| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Igor Puzanov | Q66829274 |
| P2093 | author name string | Douglas B Johnson | |
| Mark C Kelley | |||
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| Trial Watch:: Oncolytic viruses for cancer therapy | Q27021951 | ||
| Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin | Q27852360 | ||
| Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 | ||
| Final version of 2009 AJCC melanoma staging and classification | Q29614803 | ||
| Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma | Q30412300 | ||
| Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion | Q32067351 | ||
| Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial | Q33379689 | ||
| Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses | Q33924550 | ||
| Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy | Q33933665 | ||
| ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties | Q34178661 | ||
| Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. | Q34291195 | ||
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 | ||
| Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans | Q34394688 | ||
| Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity | Q34625640 | ||
| Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer | Q34849409 | ||
| CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy | Q35600445 | ||
| Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination | Q36443331 | ||
| Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress | Q36720873 | ||
| Viruses as anticancer drugs | Q36850878 | ||
| Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients | Q36925337 | ||
| A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer | Q37107332 | ||
| The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease | Q37306641 | ||
| Oncolytic virotherapy | Q38025263 | ||
| Intralesional immunotherapy for melanoma | Q38168460 | ||
| Treatment of metastatic melanoma with electrochemotherapy | Q38200101 | ||
| Topical pharmacotherapy for skin cancer: part II. Clinical applications | Q38211971 | ||
| Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials | Q38502534 | ||
| A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma | Q43114309 | ||
| Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Easter | Q44837123 | ||
| Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. | Q45740312 | ||
| Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus | Q45885739 | ||
| In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. | Q50629099 | ||
| Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. | Q52827145 | ||
| Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine | Q60311223 | ||
| Intralesional interferon-alpha therapy in advanced malignant melanoma | Q68266319 | ||
| BCG immunotherapy of malignant melanoma: summary of a seven-year experience | Q68788101 | ||
| Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF | Q71562843 | ||
| Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases | Q74394048 | ||
| Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma | Q77425510 | ||
| Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma | Q84834335 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 611-619 | |
| P577 | publication date | 2015-06-22 | |
| P1433 | published in | Immunotherapy | Q18713038 |
| P1476 | title | Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma | |
| P478 | volume | 7 |
| Q90690173 | A new oncolytic V accinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery |
| Q40080717 | A practical guide to the handling and administration of talimogene laherparepvec in Europe |
| Q93152101 | Adverse Events of Oncologic Immunotherapy and Their Management |
| Q97646406 | Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma |
| Q26863779 | Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances |
| Q36387028 | Cancer immunotherapy: Strategies for personalization and combinatorial approaches |
| Q26752277 | Cancer immunotherapy: the beginning of the end of cancer? |
| Q28066199 | Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy |
| Q38708960 | Combination of Plant Virus Nanoparticle-Based in Situ Vaccination with Chemotherapy Potentiates Antitumor Response. |
| Q50053595 | Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model. |
| Q89992810 | Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy |
| Q90681476 | Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders |
| Q90134243 | Development of oncolytic virotherapy: from genetic modification to combination therapy |
| Q90166389 | Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy |
| Q59360532 | In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma |
| Q39329609 | Interaction of molecular alterations with immune response in melanoma. |
| Q45854947 | Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. |
| Q49959107 | Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. |
| Q92173069 | Long non-coding RNAs in genitourinary malignancies: a whole new world |
| Q50089395 | Mechanisms regulating T-cell infiltration and activity in solid tumors |
| Q92923786 | Nanosystems for Improved Targeted Therapies in Melanoma |
| Q45873027 | Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives |
| Q89682703 | Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy |
| Q39456860 | Oncolytic Viruses: Exploiting Cancer's Deal with the Devil |
| Q38842126 | Oncolytic virotherapy for urological cancers |
| Q26862461 | Oncolytic virotherapy using herpes simplex virus: how far have we come? |
| Q57174025 | Oncolytic virus and PD-1/PD-L1 blockade combination therapy |
| Q94453574 | PD-1 IC Inhibition Synergistically Improves Influenza A Virus-Mediated Oncolysis of Metastatic Pulmonary Melanoma |
| Q63246477 | Preexisting Virus-Specific T Lymphocytes-Mediated Enhancement of Adenovirus Infections to Human Blood CD14+ Cells |
| Q60935215 | Prostate Cancer-Specific of DD3-driven Oncolytic Virus-harboring mK5 Gene |
| Q92223586 | Recent advances in oncolytic virus-based cancer therapy |
| Q88598727 | Regional therapies for locoregionally advanced and unresectable melanoma |
| Q64236899 | Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma |
| Q92703966 | STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells |
| Q50116255 | Talimogene Laherparepvec: First in Class Oncolytic Virotherapy |
| Q56894524 | Talimogene laherparepvec: overview, combination therapy and current practices |
| Q38589776 | The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma |
| Q52594999 | The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses. |
| Q38781281 | The safety of talimogene laherparepvec for the treatment of advanced melanoma. |
| Q40728648 | Therapeutic Cancer Vaccines |
| Q28072347 | Trial Watch-Oncolytic viruses and cancer therapy |
| Q91612728 | Viral oncolytic immunotherapy in the war on cancer: Infection control considerations |
Search more.